Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
Roche's Genentech is paying up to $1.27 billion to license AL050, Alector's experimental Parkinson's disease therapy. The deal includes $100 million upfront, with the rest tied to development and sales milestones. AL050 targets a deficiency of the GCase enzyme, which is linked to fat buildup and elevated Parkinson's risk — sending Alector's shares soaring 72% in premarket trading.
Roche's biotech arm Genentech is making a major bet on Parkinson's disease, striking a licensing deal worth up to $1.27 billion with US biotech Alector for its experimental therapy AL050. The news sent Alector's shares surging 72% in premarket trading on Monday.
AL050 is an enzyme replacement therapy designed to address a deficiency of the GCase enzyme — a shortage that leads to the buildup of certain fats and is associated with a significantly higher risk of developing Parkinson's disease. Under the agreement, Genentech gains exclusive worldwide rights to develop, manufacture, and commercialize the treatment, while Alector remains eligible for royalties.
This deal is part of a broader pipeline-building push by Roche, which in June also inked a deal worth up to $2.3 billion with Nurix Therapeutics for a blood cancer drug.
By the Numbers:
Why it matters: GCase enzyme deficiency is a well-established biological risk factor for Parkinson's disease, and enzyme replacement approaches represent a promising but largely untapped therapeutic avenue. This high-value deal signals growing industry confidence in disease-modifying strategies for Parkinson's — a condition that affects millions worldwide with limited treatment options.
